Nearly half of the Centers for Disease Control and Prevention's staff working on developmental disabilities and birth defects was laid off this month, multiple officials tell CBS News, wiping out ...

A marker linked to inflammation, C-reactive protein, may increase significantly during the follicular phase of the menstrual cycle in female patients with sickle cell disease (SCD), according to ...

A marker linked to inflammation, C-reactive protein, may increase significantly during the follicular phase of the menstrual ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex ...

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted regulatory approval for a label expansion of KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in a combination ...

Vertex Pharmaceuticals Incorporated will report its first quarter 2025 financial results on Monday, May 5, 2025 after the financial markets close. The company will host a conference call and webcast ...

Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain and other markets. Check out our ...

Learn more about whether CRISPR Therapeutics AG or Moderna, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Analysts at Precedence Research expect the gene-editing market to grow 15.7% annually and reach $40.1 billion by 2034, ...

The sudden resignation of Peter Marks, M.D., Ph.D., from the FDA branch that regulates biological products for humans ...

We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other best ...

Vertex’s effort to provide fertility support services to those on government insurance programs who want to take the ...